CAMBRIDGE, MA, USA I July 23, 2025 I Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that ...

MENLO PARK, CA, USA & GENEVA, Switzerland I July 23, 2025 I AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-profit medical research organization Drugs ...

Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of ...

BASEL, Switzerland I July 23, 2025 I Windward Bio AG, a private, clinical-stage biotechnology company committed to improving outcomes for people living with ...

HENNIGSDORF / BERLIN, Germany I July 23, 2025 I 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 ...

STUTTGART, Germany I July 24, 2025 I La Merie Publishing released its newest product entitled: Folate Receptor alpha (FRα) Targeted Therapy: a Competitor ...

HONG KONG, China I July 23, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the ...

First-in-class Flare platform designed to address targeting and resistance mechanisms in solid tumors to expand curative potential of immunotherapies for ...

HOUSTON, TX, USA I July 23, 2025 I InGeneron, Inc., a biotechnology company pioneering autologous regenerative cell therapies, today announced the publication ...

BALLERUP, Denmark I July 23, 2025 I LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has ...

BASEL, Switzerland I July 23, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), ...

MORRISTOWN, NJ, USA I July 22, 2025 I The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its ...